Keratoacanthoma - Keratoakantoma
☆ 2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
Tipisks Keratoakantoma (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) ir bieži sastopams ādas audzējs, kas pazīstams ar savu ātru augšanu un spēju regresēt pats par sevi. Tas parasti notiek gados vecākiem, gaišiem vīriešiem, kuriem ir bijuši saules bojājumi. Lai gan parastā ārstēšana ir ķirurģiska noņemšana, izmantojot izgriešanu vai Mohs mikrogrāfisko ķirurģiju, ir pieejamas dažādas citas terapijas iespējas.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ir zemas pakāpes audzējs, kas sākas noteiktos ādas dziedzeros un izskatās līdzīgs plakanas šūnu karcinoma (squamous cell carcinoma) (SCC) zem mikroskopa. Notiek debates par to, vai KA ir jāklasificē kā invazīvā plakanas šūnu karcinoma (SCC) forma.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ir otrs izplatītākais vēža veids cilvēkiem, īpaši gados vecākiem cilvēkiem. Ķirurģija parasti tiek izmantota, lai ārstētu cSCC, bet dažiem pacientiem, kuri nevar veikt operāciju vai izvēlas to neveikt, var apsvērt citas iespējas, piemēram, intralesionālu ārstēšanu. Ir izmantotas tradicionālās intralesionālās ārstēšanas metodes (metotreksāts (methotrexate) vai 5‑fluorouracils (5‑fluorouracil)), taču turpinās pētījumi par jaunām pieejām, piemēram, intralesionālo imūnterapiju un onkolītisko viroterapiju. Šeit mēs apskatīsim dažādas cSCC intralesionālas ārstēšanas metodes, sākot no klasiskām metodēm līdz progresīvām stratēģijām.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Zem mikroskopa keratoakantoms (Keratoacanthoma) ļoti atgādina plakanšūnu karcinomu. Lai gan daži patologi klasificē keratoakantoms (Keratoacanthoma) kā atsevišķu vienību, nevis ļaundabīgu audzēju, aptuveni 6% klīnisko un histoloģisko keratoakantoms (Keratoacanthoma) progresē līdz invazīvai un agresīvai plakanšūnu vēzim.
○ Diagnostika un ārstēšana
#Dermoscopy
#Skin biopsy